Literature DB >> 32599215

Who Enrolls in an Online Cancer Survivorship Program? Reach of the INSPIRE Randomized Controlled Trial for Hematopoietic Cell Transplantation Survivors.

Jean C Yi1, Brie Sullivan2, Wendy M Leisenring2, Navneet S Majhail3, Heather Jim4, Alison Loren5, Joseph Uberti6, Victoria Whalen7, Mary E D Flowers8, Stephanie J Lee8, Katie Maynard2, Karen L Syrjala8.   

Abstract

The internet can be a valuable tool in delivering survivorship care to hematopoietic cell transplantation (HCT) cancer survivors. We describe the reach of INSPIRE, an Internet and social media-based randomized controlled trial, to address healthcare and psychosocial needs of HCT survivors. All survivors 2-10 years after HCT for hematologic malignancy or myelodysplasia from 6 transplantation centers in the US were approached by mail and follow-up calls. Eligible participants had access to the Internet, an email address, and did not have active disease in the past 2 years. We used logistic regression to determine characteristics of eligible survivors who were more or less likely to enroll. Of 2578 eligible HCT survivors, 1065 (41%) enrolled in the study. The mean age of enrollees was 56.3 ± 12.6 years (range, 19 to 89 years), 52% were male, and 94% were white. Survivors less likely to enroll included those who were male, age <40 years, and who received an autologous transplant (all P < .001). Compared with white survivors, African Americans were less likely to enroll (P < .001), whereas Native Americans/Alaska Natives were more likely to join the study (P = .03). The reach of the INSPIRE program was broad, including to survivors who traditionally have less access to resources, such as Native Americans/Alaskan Natives and rural residents. Strategies are still needed to improve the enrollment of online studies of survivorship resources for males, young adults, African American, and autologous HCT survivors because their use may improve outcomes.
Copyright © 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; Hematopoietic cell transplant survivor; Oncology; Online intervention; Reach

Mesh:

Year:  2020        PMID: 32599215      PMCID: PMC7529848          DOI: 10.1016/j.bbmt.2020.06.017

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  42 in total

Review 1.  Racial and ethnic minority enrollment in randomized clinical trials of behavioural weight loss utilizing technology: a systematic review.

Authors:  D L Rosenbaum; A D Piers; L M Schumacher; C A Kase; M L Butryn
Journal:  Obes Rev       Date:  2017-05-19       Impact factor: 9.213

2.  High prevalence of distress in patients after allogeneic hematopoietic SCT: fear of progression is associated with a younger age.

Authors:  J Hefner; M Kapp; K Drebinger; A Dannenmann; H Einsele; G-U Grigoleit; H Faller; H Csef; S Mielke
Journal:  Bone Marrow Transplant       Date:  2014-01-20       Impact factor: 5.483

3.  Development and implementation of an Internet-based survivorship care program for cancer survivors treated with hematopoietic stem cell transplantation.

Authors:  Karen L Syrjala; Allison C Stover; Jean C Yi; Samantha B Artherholt; Eleni M Romano; Gary Schoch; Susan Stewart; Mary E D Flowers
Journal:  J Cancer Surviv       Date:  2011-05-05       Impact factor: 4.442

4.  Randomized Controlled Trial of Survivorship Care Plans Among Low-Income, Predominantly Latina Breast Cancer Survivors.

Authors:  Rose C Maly; Li-Jung Liang; Yihang Liu; Jennifer J Griggs; Patricia A Ganz
Journal:  J Clin Oncol       Date:  2017-04-18       Impact factor: 44.544

5.  Quality of life concerns and depression among hematopoietic stem cell transplant survivors.

Authors:  Catherine E Mosher; Katherine N DuHamel; Christine Rini; Geoffrey Corner; Joanne Lam; William H Redd
Journal:  Support Care Cancer       Date:  2010-07-27       Impact factor: 3.603

6.  Information needs and sources of information for patients during cancer follow-up.

Authors:  M A Shea-Budgell; X Kostaras; K P Myhill; N A Hagen
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

7.  Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor study.

Authors:  Navneet S Majhail; Kirsten K Ness; Linda J Burns; Can-Lan Sun; Andrea Carter; Liton Francisco; Stephen J Forman; Smita Bhatia; K Scott Baker
Journal:  Biol Blood Marrow Transplant       Date:  2007-07-20       Impact factor: 5.742

8.  Risk factors for depression and fatigue among survivors of hematopoietic cell transplantation.

Authors:  Heather S L Jim; Steven K Sutton; Paul B Jacobsen; Paul J Martin; Mary E Flowers; Stephanie J Lee
Journal:  Cancer       Date:  2016-01-27       Impact factor: 6.860

9.  Cancer survivors' use of numerous information sources for cancer-related information: does more matter?

Authors:  Danielle Blanch-Hartigan; Kelly D Blake; Kasisomayajula Viswanath
Journal:  J Cancer Educ       Date:  2014-09       Impact factor: 2.037

10.  Views of primary care providers on follow-up care of cancer patients.

Authors:  Mary Jo Nissen; Mary Sue Beran; Martin W Lee; Shubha R Mehta; Donald A Pine; Karen K Swenson
Journal:  Fam Med       Date:  2007 Jul-Aug       Impact factor: 1.756

View more
  2 in total

1.  Psychosocial and financial issues after hematopoietic cell transplantation.

Authors:  David Buchbinder; Nandita Khera
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Health-Related Quality of Life in Young Adult Survivors of Hematopoietic Cell Transplantation.

Authors:  Seth J Rotz; Jean C Yi; Betty K Hamilton; Wei Wei; Jaime M Preussler; Jan Cerny; Abhinav Deol; Heather Jim; Nandita Khera; Theresa Hahn; Shahrukh K Hashmi; Shernan Holtan; Samantha M Jaglowski; Alison W Loren; Joseph McGuirk; Jana Reynolds; Wael Saber; Bipin N Savani; Patrick Stiff; Joseph Uberti; John R Wingard; William A Wood; K Scott Baker; Navneet S Majhail; Karen L Syrjala
Journal:  Transplant Cell Ther       Date:  2022-07-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.